Joint health is critical for musculoskeletal (MSK) conditions that are affecting approximately one-third of the global population. Monitoring of joint torque can offer an important pathway for the evaluation of joint health and guided intervention. However, there is no technology that can provide the precision, effectiveness, low-resource setting, and long-term wearability to simultaneously achieve both rapid and accurate joint torque measurement to enable risk assessment of joint injury and long-term monitoring of joint rehabilitation in wider environments. Herein, we propose a piezoelectric boron nitride nanotubes (BNNTs)-based, AI-enabled wearable device for regular monitoring of joint torque. We first adopted an iterative inverse design to fabricate the wearable materials with a Poisson’s ratio precisely matched to knee biomechanics. A highly sensitive piezoelectric film was constructed based on BNNTs and polydimethylsiloxane and applied to precisely capture the knee motion, while concurrently realizing self-sufficient energy harvesting. With the help of a lightweight on-device artificial neural network, the proposed wearable device was capable of accurately extracting targeted signals from the complex piezoelectric outputs and then effectively mapping these signals to their corresponding physical characteristics, including torque, angle, and loading. A real-time platform was constructed to demonstrate the capability of fine real-time torque estimation. This work offers a relatively low-cost wearable solution for effective, regular joint torque monitoring that can be made accessible to diverse populations in countries and regions with heterogeneous development levels, potentially producing wide-reaching global implications for joint health, MSK conditions, ageing, rehabilitation, personal health, and beyond.

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to a preclinical study led by Weill Cornell Medicine investigators. The research reveals a promising strategy against this hard-to-treat malignancy, and more generally demonstrates a powerful new approach for the identification of effective regimens to treat genetically diverse cancers.